<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nurix Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/nurix-therapeutics-inc</link>
<description>Latest news and press releases for Nurix Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nurix-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a34478dffbe2df10a1f7.webp</url>
<title>Nurix Therapeutics Inc</title>
<link>https://6ix.com/company/nurix-therapeutics-inc</link>
</image>
<item>
<title>Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach Featured AACR Advances session underscores Nurix’s scientific leadership in targeted protein degradation and induced proximity pharmacology BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developin</description>
</item>
<item>
<title>Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)</description>
</item>
<item>
<title>Nurix Therapeutics to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-to-participate-in-upcoming-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-to-participate-in-upcoming-investor-conference</guid>
<pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
<description>BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference in April. Needham Virtual Healthcare ConferenceArthur T. Sands, M.D., P</description>
</item>
<item>
<title>Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-reports-fourth-quarter-210100693</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-reports-fourth-quarter-210100693</guid>
<pubDate>Wed, 28 Jan 2026 21:01:00 GMT</pubDate>
<description>First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/refractory CLL 83% objective overall response rate and progression free survival of 22.1 months demonstrate durable therapeutic effects in a large portion of patients Presented differentiated preclinical data for IRAK4 degrader GS-6791 in collaboration with Gilead Well capitalized with ca</description>
</item>
<item>
<title>Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-outlines-2026-goals-and-objectives-advancing-bexobrutideg-and-its</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-outlines-2026-goals-and-objectives-advancing-bexobrutideg-and-its</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global</description>
</item>
<item>
<title>Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-new-data-phase-1-trial-bexobrutideg-nx-5948-waldenstrom</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-new-data-phase-1-trial-bexobrutideg-nx-5948-waldenstrom</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a</description>
</item>
<item>
<title>Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-data-demonstrating-143000212</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-data-demonstrating-143000212</guid>
<pubDate>Sat, 06 Dec 2025 14:30:00 GMT</pubDate>
<description>Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population Phase 2 clin</description>
</item>
<item>
<title>Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annu...</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-new-data-demonstrating-durable-deepening-responses-phase</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-new-data-demonstrating-durable-deepening-responses-phase</guid>
<pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
<description>Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or</description>
</item>
<item>
<title>Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-webcast-review-new-and-updated-data-phase-1-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-webcast-review-new-and-updated-data-phase-1-clinical</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-leader-roger-dansey-md-its</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-leader-roger-dansey-md-its</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise SAN FRANCISCO, Nov. 10, 2025</description>
</item>
<item>
<title>Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-new-translational-data-first-human-clinical-trial-oral</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-presents-new-translational-data-first-human-clinical-trial-oral</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>Data are being presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix</description>
</item>
<item>
<title>Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-presentations-67th-american-society-hematology-ash</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-presentations-67th-american-society-hematology-ash</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Nurix Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-participate-upcoming-investor-conferences-2025-10-30</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-participate-upcoming-investor-conferences-2025-10-30</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-closing-2500-million-registered-offering-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-closing-2500-million-registered-offering-common-stock</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-2500-million-registered-offering-common-stock-2025-10-22</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-announces-2500-million-registered-offering-common-stock-2025-10-22</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-initiates-daybreaktm-pivotal-study-bexobrutideg-relapsed-or-refractory-chronic</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-initiates-daybreaktm-pivotal-study-bexobrutideg-relapsed-or-refractory-chronic</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r</description>
</item>
<item>
<title>Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress</title>
<link>https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-reports-new-clinical-data-first-class-oral-cbl-b-inhibitor-nx-1607</link>
<guid isPermaLink="true">https://6ix.com/company/nurix-therapeutics-inc/news/nurix-therapeutics-reports-new-clinical-data-first-class-oral-cbl-b-inhibitor-nx-1607</guid>
<pubDate>Sat, 18 Oct 2025 04:00:00 GMT</pubDate>
<description>NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism</description>
</item>
</channel>
</rss>